Showing results (381-390 of 398) with videos related to
Sort By:
Pageof 40
The Korean Journal of Internal Medicine|February 9, 2021
2020 Korean guidelines for the management of metastatic prostate cancerIn-Ho Kim, Sang Joon Shin, Byung Woog Kang, et al.Clinical & Experimental Metastasis|February 20, 2025
Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2EV studyOndřej Fiala, Sebastiano Buti, Kazutoshi Fujita, et al.The New England Journal of Medicine|August 18, 2021
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell CarcinomaToni K Choueiri, Piotr Tomczak, Se Hoon Park, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 8, 2023
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 TrialEmmanuel S Antonarakis, Se Hoon Park, Jeffrey C Goh, et al.Oncotarget|September 24, 2015
The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysisSeung Tae Kim, Jeeyun Lee, Mineui Hong, et al.JCO Global Oncology|October 29, 2025
Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 StudyFrancesco Massari, Matteo Rosellini, Bohuslav Melichar, et al.Frontiers in Oncology|August 11, 2025
Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 studyMaria T Bourlon, Luca Galli, Enrique Grande, et al.Targeted Oncology|September 17, 2024
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)Daniele Santini, Haoran Li, Giandomenico Roviello, et al.The New England Journal of Medicine|April 17, 2024
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell CarcinomaToni K Choueiri, Piotr Tomczak, Se Hoon Park, et al.Nature Medicine|April 21, 2015
Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomesRazvan Cristescu, Jeeyun Lee, Michael Nebozhyn, et al.Pageof 40